US-listed BioAdaptives, Inc. (OTCID: BDPT) has signed a definitive agreement to acquire Xycota Biosciences LLC, a privately held biotechnology company...

Canadian biotechnology company PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) has signed an agreement with Corealis Pharma Inc., a...

Definium Therapeutics (NASDAQ: DFTX) is set to present findings from three positive Phase 3 clinical trials of its LSD-based drug...

New preclinical findings suggest EB-003 can alter brain activity without producing some of the adverse neurological effects observed with DMT...

The Nasdaq-listed psychedelic medicine developer will participate in four major healthcare conferences during November and December as it prepares for...

Running from 2–8 November, the international event features online discussions, community gatherings and a keynote from Atai co-founder Christian Angermayer...

Now part of Rhelion Life Sciences, Canadian pharmaceutical developer Filament Health is supplying naturally derived psilocybin for clinical research worldwide,...

The Australian psychedelic-assisted therapy provider has reported record quarterly revenue of $1.42 million, expanded its national clinic network and received...

Published in JAMA, the phase 2b trial found that a single dose of the psychedelic compound 5-MeO-DMT significantly reduced depressive...

From melting clocks to impossible landscapes, Salvador Dalí's exploration of dreams and the unconscious offers an intriguing perspective on how...